Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious ...
The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...
Merck says Keytruda boosted overall survival in phase 3 ovarian cancer trial and cut death risk in bladder cancer combo data.
Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination ...
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...
Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for certain patients with ...
Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results